Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Spring Bird Delivers Transit Buses to MTR for Use in Major Construction Shuttle Operations

Spring Bird

Spring Bird has delivered six heavy-duty New Flyer D40LF transit buses to MTR, providing dedicated shuttle support for a large-scale semiconductor fabrication plant construction site. The buses will be used to safely and efficiently transport construction workers across the expansive site, reflecting the growing demand for durable, high-capacity shuttle solutions in complex infrastructure projects. The multi-bus order, fulfilled over the past year through several transactions, underscores Spring Bird’s rising role as a trusted supplier of transit buses for industrial and operational shuttle services. According to Spring Bird founder Elliott Carson, the deal came together due to “competitive pricing, fast turnaround, and strong warranty support,” all of which aligned with MTR’s high standards and tight project timelines. “This partnership with MTR is a great example of what happens when two teams are aligned in purpose and professionalism,” said Carson. “MTR had a clear vision, high standards, and a fast-moving project — and we were proud to meet that challenge. Supporting their shuttle operations with dependable, work-ready transit buses is exactly what Spring Bird is built to do.” The buses underwent standard make-ready servicing and were delivered ready for immediate deployment. While not retrofitted with low-emission or advanced telematics systems in this case, the New Flyer D40LF platform offers reliable performance, ample standing room, and durability that outperforms most traditional coach or cutaway vehicles under demanding, repetitive shuttle conditions. “Transit buses are built for this kind of work,” said Thomas Hoskins, Director of Operations at Spring Bird. “You’re moving large numbers of people, constantly, in stop-and-go patterns, sometimes on rough or temporary roads. These vehicles are designed for all-day, every-day use. They can load quickly, handle tough environments, and just keep going.” Spring Bird’s Construction Shuttle Service program highlights several key benefits of using heavy-duty transit buses in worksite transportation: Dual-door boarding allows faster loading and unloading compared to coach buses or vans. Low-floor designs increase accessibility and reduce boarding times. Higher standing capacity allows more flexible loading based on shift schedules. Cost-efficiency comes from needing fewer buses and drivers to move more people in less time. For MTR, choosing Spring Bird also meant working with a team that understands the complexity of operational logistics. “We’re proud to support partners like MTR who are helping to build the future—literally,” said Carson. “Whether it’s a long-term city transit solution or a short-term industrial project, our goal is always the same: safe, smart, dependable transportation.” The deal also adds another chapter to the Carson family’s eight-decade history in the transit industry. Spring Bird, founded by Elliott Carson in 2020, is built on a legacy that dates back to 1943 when Dean Carson began providing local transit in Los Angeles. Today, that commitment to innovation, service, and reliability lives on in Spring Bird’s growing footprint across public and private transportation sectors. About Spring Bird Spring Bird is a premier provider of transportation solutions, specializing in the sale, leasing, and service of heavy-duty transit buses and motor coaches. Drawing from the rich Carson family legacy in the transportation industry, Spring Bird offers an inventory of high-quality buses from leading manufacturers and provides customized rehabilitation services, including minor repairs, major overhauls, and technological retrofitting. Dedicated to safety, innovation, and customer satisfaction, Spring Bird addresses the unique needs of cities, transit agencies, and private operators, ensuring reliable and efficient transportation solutions. Media Contact: For more information, visit https://springbirdbus.com or contact us at press@springbirdbus.com. ### About Spring BirdSpring Bird is a premier provider of transportation solutions specializing in the sale, leasing, and service of heavy-duty transit buses and motor coaches. Drawing from the rich Carson family legacy in the transportation industry, Spring Bird offers an inventory of high-quality buses from leading manufacturers and provides customized rehabilitation services, including minor repairs, major overhauls, and technological retrofitting. Dedicated to safety, innovation, and customer satisfaction, Spring Bird addresses the unique needs of cities, transit agencies, and private operators, ensuring reliable and efficient transportation solutions. Contact Details Media Contact press@springbirdbus.com Company Website https://springbirdbus.com

April 30, 2025 10:41 AM Central Daylight Time

Image

Nutriband Inc (NASDAQ: NTRB) Solution To Fentanyl Abuse Could Translate To $200 Million In Peak Revenue

NTRB

Nutriband Inc. (NASDAQ:NTRB) is a pharmaceutical company with a specific focus on developing a portfolio of transdermal pharmaceutical products. The company’s lead product under development is AVERSA™ Fentanyl, which is on track to becoming the first-ever abuse-deterrent transdermal fentanyl patch. AVERSA Fentanyl is currently pursuing a 505(b)(2) registration pathway, which should make it eligible for a more expedited review. For context, AVERSA is Nutriband’s proprietary technology that can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with the potential for abuse, like opioids. What makes AVERSA unique is its aversive agent coating, which leverages taste aversion to deter oral abuse and accidental exposure to transdermal opioid patch products. More than 70% of fentanyl patch abusers choose oral routes to abuse, so taste aversion addresses primary routes of abuse. That means AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. In one of the company’s recent major corporate milestones, Nutriband announced that it had received notification that its patent had been granted in Macao, which protects its AVERSA abuse-deterrent transdermal technology. The technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia, as well as two regions of China: Hong Kong and Macao. Interestingly, the company hasn't been structured to follow the typical biotech standard when it comes to time and cost. The company already has two revenue-generating subsidiaries, 4P Therapeutics and Pocono Pharmaceutical, along with Active Intelligence, which specializes in sports recovery products. Nutriband’s revenues keep its development burn at a minimum. The company also owns its manufacturing and clinical development capabilities, which significantly reduces its costs for AVERSA and other technologies. Most notably, Nutriband partnered with Kindeva Drug Delivery to develop AVERSA Fentanyl, which combines Nutriband’s AVERSA abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. Kindeva Drug Delivery is a leading global contract development and manufacturing organization (CDMO) that has a rich history in pharmaceutical innovation and manufactures millions of transdermal patches distributed worldwide. This strong partnership for AVERSA Fentanyl’s commercial development has led to significant progress in the abuse-deterrent patch’s development and manufacturing. Recently the two companies revised their agreement to formalize their exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments. At the same time, Nutriband revealed that it had signed an Associate Partnership agreement with Charlotte FC, which would be instrumental in helping build visibility for its brands, such as AI Tape. Management noted, “We are very excited to partner with an organization such as Charlotte FC as an Associate Partner. Manufacturing many of our products locally in the Charlotte region through our Pocono subsidiary makes this relationship special.’’ AVERSA’s addressable market is huge, depending on how you look at it. For instance, accidental fentanyl misuse is a growing problem, as illustrated by a recent report that revealed there had been 32 cases of accidental fentanyl exposure, which occurred, resulting in 12 deaths and dozens of hospitalizations, mostly involving young children. This is where the technology comes into play, as it significantly reduces the likelihood of accidental exposure to fentanyl for children. Furthermore, AVERSA Fentanyl is well aligned with the FDA’s Opioids Action Plan mission to expand access to abuse-deterrent formulations (ADFs) and to reduce the risks of misuse not just by the patient but also by other persons who obtain opioids. Upon approval of AVERSA fentanyl, the company expects that the FDA will consider requiring all fentanyl patches to be abuse deterrent, as was required for all oxycontin generics, which could potentially translate to more market share. To put the opportunity here into better context, consider this. According to Health Advances’ assessment, once approved by the FDA, AVERSA Fentanyl is expected to reach peak annual sales of about $200 million. The company believes that conservative pricing will be a key component of capturing and maintaining market share in addition to real-world data and marketing. According to the Health Advances’ report on AVERSA Fentanyl, Nutriband can expect to comfortably charge a 20% premium versus generics while maintaining insurance coverage and support, ideally capturing the market as the safest fentanyl patch in its class. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting LLC to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

April 30, 2025 07:00 AM Eastern Daylight Time

Roberts & Ryan Earns Prestigious VETS Indexes 5-Star Employer Award for 2025

Roberts & Ryan, Inc.

Roberts & Ryan, Inc., a Service-Disabled Veteran-Owned broker-dealer, is honored to receive the 2025 VETS Indexes 5-Star Employer Award — one of the program’s highest distinctions. This award celebrates the firm’s strong and ongoing dedication to hiring, developing, and supporting veterans, military spouses, and members of the National Guard and Reserves. The VETS Indexes 5-Star Employer distinction is reserved for organizations that demonstrate a sustained and comprehensive approach to veteran employment, retention, and support. Roberts & Ryan joins a select group of top-performing employers nationwide that serve as role models for veteran-focused workforce development. “Roberts & Ryan has demonstrated exceptional support for veterans and the military-connected community, earning the organization one of the most prestigious awards possible in the VETS Indexes Employer Awards program,” said George Altman, president of VETS Indexes. “Roberts & Ryan is among the very best veteran employers, and its program can serve as a model for others.” Roberts & Ryan’s recognition highlights the firm’s ongoing efforts to support service members transitioning to civilian careers. As a veteran-founded company, Roberts & Ryan understands the unique strengths and experiences veterans bring to the workforce and actively integrates that perspective into its hiring practices, workplace culture, and community outreach. “As a Service-Disabled Veteran-Owned Business, supporting the military-connected community is part of our DNA,” said Edward D’Alessandro, CEO at Roberts & Ryan. “This award reflects our deep commitment to honoring those who serve and not just through employment, but through opportunity, growth, and lasting impact.” The VETS Indexes 5-star Employer award was granted on April 11, 2025 Recipients of the VETS Indexes Employer Awards are selected based on their responses to VETS Indexes’ groundbreaking survey, which examines the most important veteran employment metrics via a granular, objective, and data-focused questionnaire. There was no compensation paid or received for consideration of the award. To view the full list of 2025 VETS Indexes Employer Awards recipients, visit: https://vetsindexes.com/award-results-2025 About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $2.38 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, focusing primarily on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Securities are offered by Roberts & Ryan Inc., member FINRA | SIPC | MSRB | NYSE | NASDAQ. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

April 29, 2025 09:10 AM Eastern Daylight Time

TempoPay Rx Launches to Help Bridge the Prescription Drug Affordability Gap

TempoPay

TempoPay, a subsidiary of industry-leading healthcare financing and payments solutions provider PayMedix, today announced the availability of TempoPay Rx, a financing solution designed to address the growing trend in prescription drug non-adherence across the country. “We are excited to bring TempoPay Rx to the market and help create simpler and more affordable access to prescription medications for our clients,” said Tom Policelli, CEO, PayMedix. “We have seen how decreasing financial barriers to medical care has improved health outcomes for members and financial results for our employer clients. Expanding this to include pharmacy costs is the next logical step to help consumers get the care they need when they need it." With prescription drug prices rising at more than twice the rate of inflation, access and affordability for the nearly two-thirds (61%) of Americans who take prescription medications has become a serious concern. More than half (55%) of Americans report being worried about affording their prescription drug costs and nearly one-third (31%) have avoided taking medications as prescribed due to cost. TempoPay Rx is a card-based financing solution that provides enrolled employees with access to interest-free financing for prescription medications for themselves and their dependents. Employees of participating employers can receive the benefit with no credit checks or income requirements. The program offers interest and fee-free financing on a revolving basis, with flexible repayment terms made either via bank account or payroll deductions. TempoPay Rx members can access their benefit via the TempoPay app and can use either their mobile wallet or a TempoPay VISA® card to pay. PayMedix has been providing interest-free financing for in-network medical care for over 15 years. It recently completed a comprehensive study of the long-term benefits of its innovative payments solution on 45,000 active members in Wisconsin and found that not only was in-patient hospital care of PayMedix members lower than national averages by 8%, but employer medical trend increases were nearly 40% lower than the national average. “Making prescription medications more accessible by lowering the financing barriers ultimately brings the cost of healthcare down,” said Brian Marsella, President, PayMedix. “It’s a fact that medication non-adherence leads to worsening health, increased emergency room visits and hospital admissions, driving costs higher. Our clients have experienced enormous value from our medical care financing and have asked for expanded support for prescription medications. We’re proud to extend TempoPay Rx to all of our HPS employer groups this summer. Employers can further enhance this benefit with additional coverage for more funding or types of needs, ensuring comprehensive support for their employees.” TempoPay Rx will be available for all PayMedix employer groups in the HPS medical network at no additional cost beginning August 2025, with $500 in revolving funds to help subscribers afford prescription medications for themselves and their dependents. In addition to TempoPay Rx, interest-free financing for medical, dental and vision care is available through the TempoPay platform for any employer nationwide. More information can be found at www.tempopay.com. About TempoPay TempoPay partners with employers to help their employees manage their medical costs with interest-free financing and flexible repayment options. With the TempoPay Visa® card employees can take control of how they pay for healthcare without added stress, providing simple access to the financial security needed for happier, healthier lives. About PayMedix PayMedix is the only company solving the problem of high out-of-pocket costs for everyone -- providers, patients, employers, and TPAs. PayMedix is changing how people access, use, and pay for healthcare by guaranteeing payments to providers and financing for all patients. PayMedix has processed more than $5 billion in medical payments for hospital systems and physician practices and can be implemented in conjunction with any PPO or HMO network. Contact Details TempoPay Hattie Ninteau hninteau@hps.md Company Website https://www.tempopay.com

April 29, 2025 09:00 AM Eastern Daylight Time

Consulta Remédios Selects Kevel’s Retail Media Cloud to Power its Next-Generation Advertising Platform

Kevel

Kevel, the leading provider of API-based retail media ad serving technology, today announced that Consulta Remédios, Brazil's largest medicine price comparison platform, has selected Kevel's Retail Media Cloud™ to power the development and enhancement of its in-house retail media network. This partnership marks a significant step in Consulta Remédios' digital transformation strategy, enabling the platform to offer more targeted and effective advertising solutions to its partners and underscores Kevel's growing presence in the Latin American market. By leveraging Kevel's cutting-edge technology, Consulta Remédios aims to create a bespoke advertising platform that aligns with its commitment to providing accessible healthcare information and competitive pricing to Brazilian consumers. The new retail media network will enable Consulta Remédios to offer its advertising partners more targeted and effective ways to reach customers while enhancing the user experience for its millions of monthly visitors. Working closely with the Kevel team, Consulta Remédios will leverage the Retail Media Cloud™ to create seamless integrations of retail media offerings into its digital strategies. This collaboration will emphasize enhancements to the user experience across both owned and off-site channels through personalization and relevant product recommendations, utilizing Consulta Remédios' unique first-party data. James Avery, Founder and CEO of Kevel, commented, "We're excited to support Consulta Remédios as they expand their retail media capabilities. Their decision to build their retail media network on our Retail Media Cloud™ demonstrates the value in our flexible API-first platform - empowering them to quickly launch customized ad campaigns, unlock rich first-party targeting and deliver highly personalized ad experiences. We're excited to help Consulta Remédios create a truly unique advertising experience that reflects their mission of making healthcare more accessible and affordable in Brazil." Key benefits of the Consulta Remédios-Kevel partnership include: Advanced Targeting: Consulta Remédios can now harness its rich first-party data to create AI-powered customer segments, enabling highly personalized advertising campaigns. Diverse Ad Formats: Kevel's platform supports a wide range of ad units, allowing Consulta Remédios to implement native ads, sponsored listings, and contextual displays seamlessly. Rapid Deployment: With Kevel's technology, Consulta Remédios can launch custom retail media campaigns in as little as 14 days, ensuring agility during peak health seasons and promotional periods. Data Compliance and Security: Kevel's industry-leading data compliance features allow Consulta Remédios to confidently use its customer data while maintaining strict privacy standards. Improved Advertiser ROI: More precise targeting and diverse ad formats are expected to significantly enhance returns for Consulta Remédios' advertising partners. Paulo Vion, CEO at Consulta Remédios, said, "At Consulta Remédios, we're always looking for innovative ways to improve our users' experience and provide value to our advertising partners. Kevel's Retail Media Cloud™ gives us the tools and flexibility we need to build a retail media network that's uniquely tailored to the healthcare industry. We're excited about the possibilities this opens up for our business, our users, and our advertising partners." The implementation of Kevel's Retail Media Cloud™, facilitated in collaboration with local partner ShopperMedia, is expected to be completed in phases over the coming months, with the first ad placements going live later this year. About Kevel Kevel is transforming the retail media space with its cutting-edge, AI-driven ad tech infrastructure APIs that power the Retail Media Cloud™. This groundbreaking solution combines the power of AI insights with API-based technology, allowing multi-brand retailers to build dynamic, customizable ad platforms while maintaining full control of their first-party data. With Kevel, retailers can deliver personalized shopper experiences, optimize ad targeting, and unlock predictive insights to stay ahead in an ever-evolving market. Kevel's mission is rooted in the belief that every digital retailer should have the tools to create their own tailored ad platform, comparable to industry leaders like Amazon. Harnessing the power of AI for data-driven decision-making, Kevel has helped leading brands such as Chewy, The Home Depot, Edmunds, Lyft, Delivery Hero, Sonae, Slickdeals, and others launch impactful retail media networks—fostering innovation and unlocking new revenue opportunities.Learn more about how Kevel is transforming retail media at www.kevel.com. About Consulta Remédios Consulta Remédios is Brazil’s leading pharmaceutical marketplace platform, helping millions of Brazilians find the best prices on both prescription and over-the-counter medications. It also stands out as the largest aggregator of small, medium, and large pharmacy retailers in the country. With a mission to make healthcare more accessible and affordable, the platform provides transparent information on pricing, drug interactions, and nearby pharmacy locations. It serves as an essential tool for both consumers and healthcare professionals, supporting more informed decisions when purchasing medications. Contact Details Kevel Jennifer Choo Director of Marketing +1 973-343-8819 jchoo@kevel.com

April 29, 2025 09:00 AM Eastern Daylight Time

NAVEX One: Supporting HIPAA Compliance with Integrated Risk and Compliance Content

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management solutions, offers healthcare organizations the tools they need to meet rigorous data privacy and security requirements. As the regulatory environment grows increasingly complex, NAVEX announces that NAVEX One now delivers centralized policy management, employee training, and risk assessment solutions aligned with the Health Insurance Portability and Accountability Act (HIPAA) enabling simplified compliance. HIPAA establishes national standards to safeguard sensitive patient health information. To avoid costly penalties and protect patient trust, covered entities must adopt comprehensive administrative, physical, and technical safeguards. NAVEX One has long supported these efforts, offering content and capabilities that streamline compliance and strengthen privacy and security programs. “HIPAA compliance is a cornerstone of trust in healthcare. Organizations need a partner that not only helps them check the boxes but also actively supports their broader privacy and risk mitigation goals,” said A.G. Lambert, Chief Product Officer at NAVEX. “NAVEX One equips healthcare compliance professionals with the tools to develop sustainable, defensible programs that protect patient data and reduce regulatory risk.” NAVEX One empowers healthcare organizations to: Centralize and maintain privacy and security policies aligned to HIPAA. Train employees on HIPAA fundamentals and emerging risks. Assess risk and implement appropriate safeguards. Prepare for audits and investigations with robust documentation. Demonstrate ongoing compliance with automated tracking and reporting. By delivering these capabilities in a unified platform, NAVEX One streamlines HIPAA compliance, reduces administrative burden, and supports a proactive, organization-wide approach to privacy and risk management. “HIPAA requirements touch every part of an organization—from workforce training to incident reporting,” said Kyle Martin, Vice President of Risk Governance at NAVEX. “NAVEX One brings it all together in one auditable platform, giving healthcare leaders confidence they’re meeting requirements while building a strong company culture.” Learn more about NAVEX One HIPAA compliance software. NAVEX, the global leader in risk and compliance solutions, is trusted by thousands of organizations to strengthen compliance and proactively manage risk. Through the NAVEX One platform and unparalleled industry data and benchmarks, organizations are empowered to maximize the potential of their compliance and risk programs. Based in Lake Oswego, OR, with a global presence, NAVEX continues to shape the future of governance, risk and compliance. Visit our blog or follow us on LinkedIn, Facebook, and YouTube. Contact Details Navex Global scott.levesque@navex.com Company Website https://navex.com

April 24, 2025 01:22 PM Eastern Daylight Time

NeuroSense Therapeutics is on Verge of Potential Blockbuster Pharma Deal as ALS Drug Shows 58% Survival Improvement

Global Markets News

NeuroSense Therapeutics (NASDAQ: NRSN)* is in active discussions with a global pharmaceutical giant for what CEO Alon Ben-Noon calls a potentially "transformative" partnership that could catapult the company's groundbreaking ALS therapy toward commercialization, according to a shareholder letter released today. The binding term sheet announced in December has progressed to advanced discussions for a "multinational partnership" that could deliver significant upfront capital and fully fund the upcoming Phase 3 trial. While initially expected to close in Q1, the complex deal's extended timeline suggests substantial terms are being negotiated, with Ben-Noon expressing optimism about an agreement that would mark "a true inflection point" for the company. Previous neurodegenerative disease partnerships have generated substantial value for biotech companies. GSK's 2021 deal with Alector included $700 million upfront and up to $1.5 billion in milestone payments, while Biogen's 2020 Denali partnership involved $560 million upfront with $1.125 billion in potential milestones. In 2024, Eli Lilly licensed QurAlis's preclinical ALS therapy for $45 million upfront plus up to $577 million in milestones—highlighting the pharmaceutical industry's willingness to invest heavily in promising neurological treatments. Investors have compelling reasons to watch NeuroSense closely as multiple catalysts approach. PrimeC, the company's novel ALS treatment, delivered remarkable Phase 2b results showing a 33% slowing of disease progression (p=0.007) and an impressive 58% improvement in survival rates compared to placebo. These potentially game-changing outcomes position PrimeC as one of the most promising ALS therapies in development. The company's dual-track commercialization strategy adds near-term revenue potential to its long-term pipeline value. While advancing toward a global Phase 3 trial set to begin in H2 2025, NeuroSense is simultaneously pursuing fast-track approval in Canada through a special regulatory pathway designed for life-threatening conditions with limited treatment options. Commercial forecasts project potential Canadian sales of $100-150 million annually—potentially providing significant revenue while the larger global program advances. Recent scientific validation came this month at the American Academy of Neurology Annual Meeting, where distinguished neurologists presented biomarker data confirming PrimeC's mechanism of action in targeting multiple disease pathways simultaneously. PrimeC's approach combines two FDA-approved drugs (ciprofloxacin and celecoxib) in a novel formulation designed to attack ALS through multiple pathways—inflammation, iron accumulation, and RNA regulation—giving it potential advantages over single-target therapies. The drug has received coveted Orphan Drug Designation from both US and European regulators. The ALS treatment landscape represents a significant commercial opportunity, with over 30,000 patients in the US and Europe and approximately 5,000 new diagnoses annually in the US alone. With limited effective treatments currently available, successful therapies command premium pricing and substantial market share. Upcoming catalysts include Canadian regulatory progress, potential partnership announcement, and Phase 3 initiation in the second half of 2025—each representing potential value-driving events for shareholders. For investors seeking exposure to late-stage neurodegenerative disease treatments with multiple near-term catalysts, NeuroSense's progress on both the pharmaceutical partnership and regulatory fronts presents a compelling opportunity to watch closely in the coming months. Recent News Highlights from NeuroSense NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment *Disclaimer: This article was written and published by Wall Street Wire™, a promotional content and distribution brand and network. Nothing in this article constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. The operators of Wall Street Wire network are not registered brokers, dealers, or investment advisers. This article contains and is a form of paid promotional content related to NeuroSense Therapeutics and was produced as part of their paid subscription to Wall Street Wire. This article has not been reviewed or approved by NeuroSense Therapeutics prior to publication. The information in this article is based on publicly available news reports and filings which have not been independently verified by us. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. Contact Details Wall Street Wire | Coverage Desk media.globalmarkets@gmail.com

April 24, 2025 10:36 AM Eastern Daylight Time

News Release

Van Ness Corridor Emerges as San Francisco’s Premier Medical Destination

The Hoyt Organization

The Van Ness corridor has become one of San Francisco’s most dynamic medical and healthcare destination, anchored by the world-class Sutter Health’s California Pacific Medical Center and supported by an expanding ecosystem of medical office spaces and care providers. A highlight of this transformation is the 45,000 square feet of premium medical office space currently available at 939 Ellis St., making it the largest contiguous medical space on the market in San Francisco today. Strategically located just steps away from Sutter’s Van Ness campus, 939 Ellis offers an unparalleled opportunity for medical groups, specialty clinics, and healthcare innovators looking to establish a presence in the city’s fastest-growing healthcare hub. Ellis’ central location provides convenience for patients commuting from East Bay, the Peninsula, and Marin County. Connectivity to the Van Ness Corridor has never been better with the 2022 launch of the Van Ness Bus Rapid Transit, a 1.96-mile route running north-south featuring dedicated center bus lanes and nine stations. “The synergy between the neighborhood’s thriving healthcare community and access to transportation is reshaping the Van Ness corridor into a one-stop destination for high-quality patient care,” said Kurt Hackett, Vice President of Asset Management with Rethink Healthcare Real Estate, a private investment group that owns 939 Ellis St. “Whether it’s primary care, outpatient specialties, diagnostics, or wellness services, everything patients and providers need is increasingly concentrated in this central, transit oriented neighborhood.” The building, which is already about half occupied by Kaiser Permanente, comes to market amid a notable resurgence in San Francisco’s economy as the city positions itself for a boom in AI investments. The increase in business is being further fueled by the return-to-office trend and a growing belief that San Francisco is on the right track, according to recent surveys. Recently elected Mayor Daniel Lurie has spearheaded many new efforts that are working to bring businesses and visitors back to the world class downtown. As demand for centrally located, modern medical space continues to rise, the Van Ness corridor stands out as a focus for San Francisco’s healthcare future. “We could not be more bullish on this location,” said Jonathan Winer, President of Rethink Healthcare Real Estate. “Not only is San Francisco’s reemergence as a hotbed of business activity a catalyst for those looking to treat patients locally, but the ease of transit has made the Van Ness Corridor a convenient destination for doctors and patients, alike, who are coming from the outskirts of the city or the suburbs.” 939 Ellis St. offers flexible, build-ready medical office suites that can accommodate a range of specialties. It boasts a scenic rooftop terrace and available parking. For leasing inquiries at 939 Ellis St., contact Trask Leonard, president and CEO of Bayside Realty Partners at tleonard@baysiderp.com or Caroline Doyle, senior vice president of Bayside Realty Partners, at cdoyle@baysiderp.com. Contact Details The Hoyt Organization Andrew King +1 914-513-6895 aking@hoytorg.com Company Website https://rethink-capital.com/healthcare-real-estate/

April 23, 2025 10:20 AM Pacific Daylight Time

Silexion Therapeutics Collaborates with Multi Billion Dollar Clinical Development Player, Advancing Revolutionary Cancer Treatment Toward Clinical Trials

Global Markets News

Silexion Therapeutics' (NASDAQ: SLXN) * groundbreaking RNAi therapy showing 70-80% tumor reduction takes major step forward with global manufacturing collaboration; Wall Street analysts reportedly maintain $5 price target representing potential 500% upside as company targets $470B precision medicine market Game-Changing Partnership Announcement In a strategic move that significantly advances its revolutionary cancer treatment pipeline, Silexion Therapeutics (NASDAQ: SLXN) announced today a collaboration with global therapeutics giant Catalent to optimize and manufacture its breakthrough KRAS-targeting therapy SIL204. This partnership represents a critical acceleration toward human clinical trials, expected to begin in the first half of 2026. The collaboration will leverage Catalent's state-of-the-art Limoges, France facility—a European center of excellence for complex biologics formulation—to optimize both systemic and intratumoral delivery formulations of SIL204, supporting Silexion's innovative dual-route strategy targeting both primary tumors and metastases. "Our collaboration with Catalent represents a significant advancement in our SIL204 development program," said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. "Catalent's expertise in complex formulation development will be instrumental as we work toward our goal of initiating human clinical trials in the first half of 2026." Disrupting the "Undruggable": Silexion's Breakthrough Approach to KRAS Mutations Silexion's technology stands at the frontier of precision oncology, targeting KRAS mutations—long considered the "holy grail" of cancer targets and present in over 90% of pancreatic cancers. While competitors have developed small molecule inhibitors that target only specific KRAS mutations (primarily G12C, found in just 1-2% of pancreatic cancers), Silexion's RNA interference approach silences multiple KRAS mutations at the genetic level. Recent preclinical data revealed SIL204's remarkable efficacy across multiple pancreatic cancer models: 70% reduction in tumor burden in AsPC-1 models (KRAS G12D mutation) Significant dose-dependent tumor reduction in Panc-1 models (KRAS G12D mutation) 80% tumor reduction in BxPC-3 models Most critically, for the first time, Silexion demonstrated SIL204's ability to reduce metastatic spread to secondary organs—a game-changing advancement that could transform treatment paradigms for aggressive pancreatic cancer. Dual-Route Strategy: A Comprehensive Attack on Cancer Silexion recently unveiled its expanded development plan for SIL204, integrating both systemic administration for targeting metastatic progression and intratumoral delivery for attacking primary tumors—a comprehensive approach unique in KRAS-targeted therapies. The orthotopic models used in Silexion's breakthrough studies better represent human pancreatic cancer biology by allowing tumors to develop in their native environment. This stands in contrast to subcutaneous xenograft models, where tumors grow beneath the skin rather than in the organ of origin. This expanded approach is supported by SIL204's demonstrated ability to maintain therapeutic levels for over 56 days from a single administration—an unprecedented achievement in RNAi therapeutics. Massive Market Opportunity in Precision Oncology The partnership with Catalent positions Silexion advantageously within the rapidly growing precision medicine market, projected to surge from $102 billion in 2024 to $470 billion by 2034, growing at a CAGR of 16.5%. Within this broader market, KRAS-driven cancers represent a substantial unmet need, with the market for KRAS inhibitors expected to grow at an impressive 36% CAGR, reaching $10 billion by 2032. Recent years have seen unprecedented consolidation in precision oncology, with big pharma aggressively seeking innovative assets: Pfizer's landmark $43 billion acquisition of Seagen in 2023 AbbVie's $10.1 billion purchase of Immunogen Numerous other multi-billion dollar transactions for targeted oncology assets With major pharmaceutical companies collectively holding over $170 billion in cash reserves, according to reports, the M&A environment remains highly favorable for innovative companies developing breakthrough cancer therapeutics. Wall Street's Bullish Outlook: Over 500% Potential Upside Wall Street analysts appear to recognize Silexion's potential, with Maxim Group maintaining a Buy rating and a $5 price target—representing a remarkable premium of over ~500% from today's pre market price. This seemingly bullish stance reflects confidence in Silexion's differentiated technology, promising preclinical data, and clear strategic roadmap. Silexion's partnership with Catalent adds credibility to its development roadmap, which includes toxicology and pharmacodynamic studies throughout 2025, regulatory submissions to the Israel Ministry of Health in H2 2025 and the European Union in H1 2026, and the initiation of human clinical trials in 2026. A Potential Industry Game-Changer to Watch Silexion Therapeutics stands at a pivotal moment in its development journey. With groundbreaking preclinical data demonstrating efficacy against both primary tumors and metastases, a clear strategic roadmap to clinical trials, and now a global manufacturing partnership with Catalent, the company is positioned at the intersection of high unmet medical need and significant market opportunity. As pancreatic cancer remains one of the deadliest malignancies with a dismal five-year survival rate below 13%, Silexion's innovative approach targeting multiple KRAS mutations could represent a transformative advancement in treatment paradigms—potentially reshaping the landscape for one of oncology's most challenging diseases. For investors seeking exposure to next-generation precision oncology, Silexion represents a unique opportunity to participate in the development of a potentially disruptive technology addressing one of medicine's most significant challenges. News Highlights from Silexion: - Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities - Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data - Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models *Disclaimer: This article was written and published by Wall Street Wire™, a promotional content and distribution brand and network. Nothing in this article constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. The operators of Wall Street Wire network are not registered brokers, dealers, or investment advisers. This article contains and is a form of paid promotional content related to Silexion Therapeutics and was produced as part of their paid subscription to Wall Street Wire. This article has not been reviewed or approved by Silexion Therapeutics prior to publication. The information in this article is based on publicly available news reports and filings which have not been independently verified by us. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. Contact Details Wall Street Wire | Coverage Desk media.globalmarkets@gmail.com

April 23, 2025 09:54 AM Eastern Daylight Time

1 2 3 4 5 ... 318